CRISPR Therapeutics AG
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Samarth Kulkarni
- Full Time Employees
- 393
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Baarerstrasse 14 Zug ZG Switzerland 6300
- IPO Date
- Oct 19, 2016
- CIK
- 0001674416
- Website
- crisprtx.com
- Similar Companies
- Business
- CRISPR Therapeutics AG (Nasdaq: CRSP) is a biotechnology company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. Founded in 2013 and headquartered in Zug, Switzerland, the company operates globally with research and development facilities in Boston and San Francisco, California, and a state-of-the-art manufacturing site in Framingham, Massachusetts. Its lead approved therapy, exagamglogene autotemcel (exa-cel, commercialized as CASGEVY in collaboration with Vertex Pharmaceuticals), is an autologous ex vivo CRISPR/Cas9 gene-edited cell therapy approved in multiple countries for eligible patients with sickle cell disease and transfusion-dependent beta-thalassemia; the company advances a broad pipeline including wholly owned and partnered programs across hemoglobinopathies such as next-generation conditioning agents and in vivo HSC editing; immuno-oncology and autoimmune therapies like CTX112 (anti-CD19 allogeneic CAR T) and other CAR T candidates targeting CD19, CD70, and glypican-3; in vivo cardiovascular programs including CTX310 (ANGPTL3), CTX320 (Lp(a)), and CTX340 (AGT for refractory hypertension); additional in vivo candidates such as CTX450 (ALAS1 for acute hepatic porphyria), CTX460 (SERPINA1 for alpha-1 antitrypsin deficiency), and undisclosed programs in rare and common diseases; regenerative medicine offerings like CTX211 and CTX213 (allogeneic gene-edited stem cell-derived therapies for type 1 diabetes); and partnered siRNA and other initiatives including SRSD107 (Factor XI for thromboembolic conditions with Sirius Therapeutics) and programs in Duchenne muscular dystrophy, myotonic dystrophy type 1, cystic fibrosis, and type 1 diabetes licensed to Vertex. In 2025, CRISPR Therapeutics expanded its portfolio through a strategic collaboration with Sirius Therapeutics, involving a $25 million cash upfront and $70 million equity investment to co-develop and commercialize novel siRNA therapies starting with SRSD107, with options for two additional programs and shared costs/profits; the company also continues global commercialization of CASGEVY, achieving regulatory approvals in nine countries and treating over 100 patients as of mid-2025 while advancing clinical milestones for CTX112, CTX310, CTX320, and others amid strong cash reserves exceeding $1.7 billion.
Company News
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
3 Stocks With the Most Upside by the End of 2026
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.
Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead